APA (7th ed.) Citation

Jeitany, M., Leroy, C., Tosti, P., Lafitte, M., Le Guet, J., Simon, V., . . . Sirvent, A. (2018). Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO molecular medicine, 10(4), 1-n/a. https://doi.org/10.15252/emmm.201707918

Chicago Style (17th ed.) Citation

Jeitany, Maya, et al. "Inhibition of DDR1‐BCR Signalling by Nilotinib As a new Therapeutic Strategy for Metastatic Colorectal Cancer." EMBO Molecular Medicine 10, no. 4 (2018): 1-n/a. https://doi.org/10.15252/emmm.201707918.

MLA (9th ed.) Citation

Jeitany, Maya, et al. "Inhibition of DDR1‐BCR Signalling by Nilotinib As a new Therapeutic Strategy for Metastatic Colorectal Cancer." EMBO Molecular Medicine, vol. 10, no. 4, 2018, pp. 1-n/a, https://doi.org/10.15252/emmm.201707918.